Related Experiment Videos
Receptors for human plasminogen on the biological response modifier OK-432
M Ullberg1, W Tewodros, G Kronvall
1Department of Clinical Microbiology, Karolinska Hospital, Stockholm, Sweden.
Abstract:
The biological response modifier OK-432, constituting cell wall fragments from a group A Streptococcus strain and used in anticancer therapy trials, was tested for its ability to interact with different plasma proteins. The uptake of 125I-labelled protein was measured using a panel of six different plasma proteins all known to react with receptors on a majority of streptococcal strains. Of the proteins tested, plasminogen demonstrated the most substantial uptake, with uptake values ranging from 70 to 79%. A slight interaction with fibrinogen was also detected whereas no significant interaction was found with either human immunoglobulin (Ig)A, IgG, serum albumin, or mouse albumin. The results with plasminogen suggest the possibility of a new explanation of the antitumor activity described for OK-432.
Insights
The biological response modifier OK-432 interacts significantly with plasminogen, a key finding that may explain its anticancer effects. This study investigated OK-432
Area of Science:
- Immunology
- Biochemistry
- Oncology
Background:
- OK-432, derived from Streptococcus, is a biological response modifier used in cancer therapy trials.
- Its mechanism of action, particularly its interaction with host proteins, requires further elucidation.
Purpose of the Study:
- To investigate the interaction between OK-432 and various plasma proteins.
- To identify specific plasma proteins that bind to OK-432.
- To explore potential new explanations for OK-432's antitumor activity.
Main Methods:
- Utilized 125I-labelled plasma proteins to quantify binding.
- Tested six different human plasma proteins known to interact with streptococcal strains.
- Measured protein uptake by OK-432.
Main Results:
- Plasminogen showed the most substantial uptake by OK-432, ranging from 70% to 79%.
- A minor interaction was observed between OK-432 and fibrinogen.
- No significant interaction was detected with human IgA, IgG, serum albumin, or mouse albumin.
Conclusions:
- Plasminogen is a primary plasma protein interacting with OK-432.
- This interaction offers a potential novel mechanism underlying OK-432's antitumor efficacy.
- Further research into the OK-432-plasminogen relationship is warranted.